Episodic or chronic? Distinguishing between the 2 types of migraine is essential to ensure optimal treatment. Meet Abigail and Martin. Who has which headache?
FDA Submission Planned for Nonopioid Cebranopadol Following Positive Phase 3 Results: Tris Pharma Update
Positive findings for postsurgical acute pain relief from the pivotal phase 3 ALLEVIATE-2 trial complete the development program, allowing plans for NDA submission.
Distress Signals: How to Help a Clinician Colleague in Need
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Rebekah Bernard, MD, a family physician and national speaker on physician wellness.
Donanemab Treatment Linked to Increase Risk of Serious ARIA in Alzheimer Disease
Analysis of data from the donanemab TRAILBLAZER development program underscores the essential role of patient selection and treatment monitoring.
Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.
FDA Pre-NDA Meeting for AXS-05 in Alzheimer's Disease Sets Stage for sNDA Submission in Q3 2025
Axsome Therapeutics reported that the FDA feedback supports the company's regulatory package for a sNDA for the dextromethorphan/bupropion combination.
Nonopioid Analgesic Pilavapadin Advances to Phase 3 for Diabetic Neuropathy
The investigational once-daily oral analgesic, a potent inhibitor of a novel target for neuropathic pain, achieved meaningful pain reduction vs placebo.